Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers
Status:
COMPLETED
Trial end date:
2025-02-08
Target enrollment:
Participant gender:
Summary
This Phase 1 study in healthy adult volunteers is planned to evaluate the safety, tolerability, and pharmacokinetics (PK) of AV078, a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1).
The study will begin with a standard exploration of safety and tolerability in sequential single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. Subsequent cohorts will collect PK data to evaluate food effects and potential drug-drug interactions relevant to AV078.